Bellerophon Therapeutics is a therapeutics company focused on developing products that address medical needs in the treatment of cardiopulmonary diseases. Co.'s focus is the continued development of its nitric oxide therapy for patients with or at risk of pulmonary hypertension (PH) using its proprietary pulsatile nitric oxide delivery platform, INOpulse. Co.'s INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Co. is developing its INOpulse program for the treatment of three additional indications: chronic thromboembolic PH, PH associated with sarcoidosis and PH associated with pulmonary edema from high altitude sickness. The BLPH average annual return since 2015 is shown above.
The Average Annual Return on the BLPH average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BLPH average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BLPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|